Karyopharm Therapeutics stock (US48576U1060): Q1 earnings due May 14

Karyopharm Therapeutics (Nasdaq: KPTI) is set to report its Q1 2026 earnings on May 14, 2026, ahead of an anticipated per-share loss of -$1.45, according to analyst estimates as of AInvest as of May 2026. The commercial-stage biotech focuses on novel cancer therapies using its SINE platform. Shares closed at $8.51 on May 11, 2026, reflecting a 0.7% gain from the prior session, per Robinhood as of 05/11/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Karyopharm Therapeutics: core business model

Karyopharm Therapeutics develops cancer therapies based on its Selective Inhibitor of Nuclear Export (SINE) compound series. The lead product, selinexor (XPOVIO), is approved for multiple myeloma and other indications in the US and Europe. The company, founded in 2008, transitioned to commercial operations under CEO Michael Kauffman, M.D., as noted in MarketBeat as of 05/14/2026.

Senior management will present at the H.C. Wainwright 4th Annual BioConnect and RBC 2026 Global Healthcare conferences on May 19, 2026, via fireside chats, webcast live on the IR site, per the PR Newswire release as of May 2026. This follows the upcoming earnings, providing a platform to discuss results and pipeline progress.

Main revenue and product drivers for Karyopharm Therapeutics

Revenue primarily stems from XPOVIO sales for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma. Strategic collaborations aim to expand SINE tech into other oncology and neurodegenerative areas. Market cap stood at $106.23 million as of recent data from Robinhood as of 05/11/2026, with shares at $8.51.

On May 11, 2026, KPTI traded between $8.45 and $9.25 on Nasdaq, with volume at 131.75K shares versus an average of 87.46K. The P/E ratio was -0.43, reflecting ongoing losses typical for clinical-stage biotechs.

Industry trends and competitive position

The oncology sector sees robust demand for targeted therapies, with multiple myeloma treatments evolving rapidly. Karyopharm's nuclear export inhibition differentiates it from competitors like CAR-T therapies or proteasome inhibitors. US investors track KPTI for exposure to innovative biotech plays listed on Nasdaq.

Conclusion

Karyopharm Therapeutics approaches its Q1 2026 earnings release on May 14 with investor focus on selinexor uptake and pipeline updates. Recent share gains and conference appearances signal ongoing engagement. The Nasdaq-listed biotech remains a watch for US investors monitoring oncology innovation, amid a 52-week range of $3.51 to $13.20 as of Robinhood data as of 05/11/2026.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.